EP3759496A1 - Procédé in vitro de détection d'une défaillance de la barrière intestinale chez des animaux par détermination de l'ovotransferrine - Google Patents

Procédé in vitro de détection d'une défaillance de la barrière intestinale chez des animaux par détermination de l'ovotransferrine

Info

Publication number
EP3759496A1
EP3759496A1 EP19706290.4A EP19706290A EP3759496A1 EP 3759496 A1 EP3759496 A1 EP 3759496A1 EP 19706290 A EP19706290 A EP 19706290A EP 3759496 A1 EP3759496 A1 EP 3759496A1
Authority
EP
European Patent Office
Prior art keywords
intestinal
animal
sample
samples
ovotransferrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19706290.4A
Other languages
German (de)
English (en)
Inventor
Monika FLÜGEL
Stefan Pelzer
Frank Thiemann
Filip Van Immerseel
Richard Ducatelle
Evy GOOSSENS
Bart DEVREESE
Griet DEBYSER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Evonik Operations GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Operations GmbH filed Critical Evonik Operations GmbH
Publication of EP3759496A1 publication Critical patent/EP3759496A1/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Definitions

  • the present invention relates to an in vitro method for detecting intestinal barrier failure in animals. More specifically, the present invention pertains to an acute phase protein (APP)-based method for evaluating the gut health status of an individual animal and of an animal population, respectively.
  • APP acute phase protein
  • Intestinal health is critically important for the welfare and performance of livestock animals. Enteric diseases that affect the structural integrity of the gastrointestinal tract (GIT) lead to high economic losses due to reduced weight gain, poor feed conversion efficiency, increased mortality rates and greater medication costs (M'Sadeq, S.A., Wu, S., Swick, R.A. & Choct, M. (2015). Towards the control of necrotic enteritis in broiler chickens with in-feed antibiotics phasing-out worldwide. Animal Nutrition, 1 , 1-1 1 ; Timbermont, L, Haesebrouck, F., Ducatelle, R. & Van Immerseel, F. (201 1 ). Necrotic enteritis in broilers: an updated review on the pathogenesis. Avian Pathol, 40, 341-347).
  • An intact intestinal barrier provides a number of physiological and functional features, including nutrient digestion and absorption, host metabolism and energy generation, a stable microbiome, mucus layer development, barrier function, and mucosal immune responses (Kogut, M. H. and R. J. Arsenault (2016). Editorial: Gut health: The new paradigm in food animal production. Frontiers in Veterinary Science 3 (AUG)).
  • the gut serves as a selective barrier to take up nutrients and fluids into the body, while excluding undesirable molecules and pathogens. Therefore, proper gut barrier function is essential to maintain optimal health and balance throughout the body, and represents a key line of defense against foreign antigens from the environment.
  • Coccidiosis and necrotic enteritis probably are the most common enteric diseases of poultry (Dalloul, R.A. & Lillehoj, H.S. (2006). Poultry coccidiosis: recent advancements in control measures and vaccine development. Expert Rev Vaccines, 5, 143-163; Williams, R.B. (2005). Intercurrent coccidiosis and necrotic enteritis of chickens: rational, integrated disease management by maintenance of gut integrity. Avian Pathol, 34, 159-180). In poultry, coccidiosis can be caused by multiple species belonging to the genus Eimeria, from which Eimeria acervulina, E. maxima and E.
  • tenella are the most common species in intensively reared broilers. Depending on the species, the lesions can range from a limited malabsorptive enteritis (E. acervulina) to more severe inflammation of the intestinal wall (E. maxima) and even extensive caecal haemorrhage and death (E. tenella) (Chapman, H.D. (2014). Milestones in avian coccidiosis research: a review. Poult Sci, 93, 501-51 1 ). Furthermore, the presence of Eimeria species can also exacerbate the outcome of co-infection with bacterial pathogens such as Clostridium perfringens (Moore, R.J. (2016).
  • NE is the most common clostridial enteric disease in poultry, which typically occurs in broiler chickens. The disease is caused by C. perfringens and can occur either as an acute clinical or as a mild subclinical form. Acute NE typically leads to a massive increase in flock mortality. The more common subclinical form is characterized by multifocal necrosis and inflammation of the small intestine with a significant decline in growth performance.
  • enteric diseases or conditions in livestock animals which are leading to mucosal damage, such as severe bacterial overgrowth in the small intestine, all forms of excessive gut inflammation, exposure to mycotoxins, and every condition which leads to intestinal barrier failure.
  • intestinal barrier failure might enable normal inhabitants of the GIT, like Enterococcus caecorum to invade the systemic circulation. This can lead to further diseases like arthritis and osteomyelitis and finally lead to lower performance of the animals or the animal flock, respectively.
  • a marker, or a set of markers, that can accurately detect intestinal barrier failure or intestinal inflammation and concomitant perturbation of the intestinal integrity at an early stage would thus be highly desirable.
  • one objective of the present invention is to provide an in vitro method for detecting intestinal barrier failure in animals, the method comprising the following steps:
  • the at least one protein marker comprises or consists of ovotransferrin or a functional fragment thereof
  • an increased amount of said at least one protein marker contained in said sample versus a reference sample indicates intestinal barrier failure.
  • An additional aspect of the present application is the use of ovotransferrin or of functional fragments thereof as intestinal markers for detecting intestinal barrier failure in an animal subject or in an animal population.
  • a further objective of the present invention is the provision of an in vitro method for detecting the extent of intestinal barrier failure in animals, the method comprising the following steps:
  • the at least one protein marker comprises or consists of ovotransferrin or a functional fragment thereof
  • the amount of said at least one protein marker contained in the sample indicates the extent of the intestinal barrier failure.
  • the present invention provides an in vitro method for monitoring the status of the intestinal barrier in animals, the method comprising the following steps: a) collecting intestinal sample material of a specific animal or of an animal population at consecutive points in time;
  • the at least one protein marker comprises or consists of ovotransferrin or a functional fragment thereof.
  • the present inventors have unexpectedly found that the amount of acute phase protein (APP)- based markers contained in sample material of animal origin correlates with the manifestation of intestinal barrier failure.
  • APP acute phase protein
  • the amount of ovotransferrin, or functional fragments thereof, in intestinal sample material of animal origin correlates with intestinal barrier failure.
  • the inventors have found that an increase in the amount of ovotransferrin, or functional fragments thereof, contained in intestinal sample material of animal origin versus a reference sample indicates intestinal barrier failure.
  • the present invention pertains to an in vitro method for detecting intestinal barrier failure in animals, the method comprising the following steps:
  • the at least one protein marker comprises or consists of ovotransferrin or a functional fragment thereof
  • an increased amount of said at least one protein marker contained in said sample versus a reference sample indicates intestinal barrier failure.
  • intestinal barrier failure refers to conditions in which the intestinal barrier function is significantly impaired (e.g. due to oxidative stress, poorly digestible protein, coccidiosis, etc.); and comprises conditions of intestinal barrier dysfunction, intestinal leakages/permeability and conditions caused by histopathologic injuries. Intestinal barrier failure is often associated with inflammatory processes.
  • intestinal barrier failure and“gut barrier failure” may be used interchangeably.
  • the reference sample is a species-specific control representing an intact intestinal barrier or gut barrier.
  • Suitable reference samples are samples obtained from an individual animal or from an animal population of the same animal species or sub-species, whereby said animal or said animal population has a proven intact intestinal barrier.
  • a reference sample may be taken within an animal trial from an animal of a non- treated control, which was checked via pathology, histopathology and/or other measures to have no signs of intestinal barrier failure.
  • the ovotransferrin markers may be detected and quantified using the commonly known, conventional techniques, such as immunoassays like ELISA (Enzyme-linked Immunosorbent Assay), lateral flow assays, mass spectrometry (MS) analyses, or any method enabling the detection of proteins or functional fragments thereof.
  • immunoassays like ELISA (Enzyme-linked Immunosorbent Assay), lateral flow assays, mass spectrometry (MS) analyses, or any method enabling the detection of proteins or functional fragments thereof.
  • the ovotransferrin, or functional fragments thereof is detected and quantified via ELISA.
  • monoclonal antibodies enables a specific detection in the complex sample matrix used for the analysis.
  • the method of the present invention may be used for determining whether or not an individual animal suffers from intestinal barrier failure. In that case, the intestinal sample material originates from an individual animal.
  • the individual animal may for example be a pet or domestic animal, a farm animal as occurring in live stocks, a wild-living animal or a zoo animal. Further, animal individuals being transported for slaughter or for re-location may be examined using the above method.
  • the individual animal is an avian subject.
  • the avian subject to be tested is preferably poultry.
  • Preferred poultry according to the invention are chickens, turkeys, ducks and geese.
  • the poultry can be optimized for producing young stock. This type of poultry is also referred to as parent and grandparent animals.
  • Preferred parent and grandparent animals are, accordingly, (grand)parent broilers, (grand)parent ducks, (grand)parent turkeys and (grand)parent geese.
  • the poultry according to the invention can also be selected from fancy poultry and wild fowl.
  • Preferred fancy poultry or wild fowl are peacocks, pheasants, partridges, guinea fowl, quails, capercailzies, goose, pigeons and swans.
  • Further preferred poultry according to the invention are ostriches and parrots. Most preferred poultry according to the invention are broilers.
  • the intestinal sample material obtained from an individual animal may be selected from the group consisting of gut content samples, samples of bodily excrements and solutions or suspensions thereof; and from materials being contaminated with bodily excrements.
  • gut content is to be understood as the content of the small intestine, the content of the large intestine and/or the content of the caecum. Methods for taking such gut content samples are known in the art.
  • bodily excrements are fecal or cecal excrements.
  • Materials being contaminated with bodily excrements are, for example, dust samples, swab samples, litter samples, liquid manure samples, fur samples, feather samples and skin samples.
  • the term“litter” is to be understood as a mixture of animal excrements with the bedding material.
  • the term “litter samples” refers to excremental droppings from an individual animal.
  • liquid manure samples refers to an excremental sample containing feces and urine from an individual animal.
  • Samples from individual animals can be taken either directly from the animal, e.g. with swabs.
  • the sample material can be collected from the floor of the pen, cage or slat. The sample material has to be assignable to the investigated animal.
  • the intestinal sample material used for determining whether or not an individual animal suffers from intestinal barrier failure is feces.
  • gut content samples e.g. samples from the small intestine, samples from the large intestine and/or samples from the caecum.
  • Suitable sample volumes are, for example, 0.05 ml to 20 ml or 0.1 to 20 ml, in particular 0.2 to 10 ml, preferably 0.5 to 5 ml.
  • Suitable sample masses are, for example 0.05 g to 20 g or 0.1 to 20 g, in particular 0.2 to 10 g, preferably 0.5 to 5 g.
  • the method is used for determining whether or not an animal population suffers from intestinal barrier failure. In that case, the sample material originates from the group of animals to be tested.
  • animal population refers to a group of animal individuals belonging to the same species.
  • the animal population may for example be a group of pets or domestic animals as occurring in animal breeding, a group of farm animals as occurring in livestock production or in livestock breeding, or a group of wild-living animals or zoo animals.
  • the animal population is an animal flock as occurring in livestock production processes.
  • the animal population or the animal flock can be an avian flock; a flock of sheep, goat or cattle, a flock of horses or a flock of pigs.
  • the animal population is an avian population.
  • the animal population preferably is an avian flock.
  • the avian flock according to the invention is preferably poultry.
  • Preferred poultry according to the invention are chickens, turkeys, ducks and geese.
  • the poultry can be optimized for producing young stock. This type of poultry is also referred to as parent and grandparent animals.
  • Preferred parent and grandparent animals are, accordingly, (grand)parent broilers, (grand)parent ducks, (grand)parent turkeys and (grand)parent geese.
  • the poultry according to the invention can also be selected from fancy poultry and wild fowl.
  • Preferred fancy poultry or wild fowl are peacocks, pheasants, partridges, guinea fowl, quails, capercailzies, goose, pigeons and swans.
  • Further preferred poultry according to the invention are ostriches and parrots. Most preferred poultry according to the invention are broilers.
  • the method of the present invention is particularly suitable for determining the health status of an animal population via bulk testing.
  • the term“bulk testing” refers to a test method, wherein the sample material is a pooled sample of an animal population.
  • A“pooled sample” in the context of this embodiment is to be understood as a composite sample from randomly selected separate samples, one sample taken with one or several moistened fabric swabs or pooled samples made up of separate samples of fresh samples taken at random from a number of sites in the house or space in which the animal population or the animal flock is kept. It may be necessary that the sample material is homogenized prior to sample analysis. Suitable homogenization techniques are known in the art.
  • the pooled samples reflect the amount of ovotransferrin present in the animal population.
  • the sample material obtained from an individual animal may be selected from the group consisting of gut content samples, samples of bodily excrements and solutions or suspensions thereof; and from materials being contaminated with bodily excrements.
  • Materials being contaminated with bodily excrements are, for example, dust samples, swab samples, litter samples, liquid manure samples, fur samples, feather samples and skin samples.
  • the term“litter samples” refers to mixed excremental droppings in the pen, cage or slat.
  • the term“liquid manure samples” refers to mixed excremental samples containing feces and urine.
  • These litter samples can, for example, be collected from an animal population using the overshoe method or using litter grabs at different places in the pen.
  • Boot swabs being sufficiently absorptive to soak up moisture are particularly suitable for collecting pooled animal samples. Tube gauze socks are also acceptable.
  • the excremental samples may be collected by a conveying belt.
  • the sample material used for determining whether or not an animal population suffers from intestinal barrier failure is feces.
  • the sample material is a pooled fecal sample deriving from an avian flock.
  • pooled gut content samples e.g. pooled samples from the small intestine, pooled samples from the large intestine and/or pooled samples from the caecum.
  • Suitable sample volumes are, for example, 0.1 to 20 ml, in particular 0.2 to 10 ml, preferably 0.5 to 5 ml.
  • Suitable sample masses are, for example 0.1 to 20 g, in particular 0.2 to 10 g, preferably 0.5 to 5 g.
  • the stabilizing agent is added to the sample immediately after sample collection.
  • one specific embodiment of the present application pertains to an in vitro method for detecting intestinal barrier failure in an avian flock, the method comprising the following steps:
  • the present invention provides an in vitro method for detecting the extent of intestinal barrier failure in animals, the method comprising the following steps:
  • the at least one protein marker comprises or consists of ovotransferrin or a functional fragment thereof
  • the amount of said at least one protein marker contained in the sample indicates the extent of the intestinal barrier failure.
  • Suitable sample materials testing parameters and -conditions are as defined above.
  • the intestinal sample material is a pooled fecal sample deriving from an avian flock and the at least one protein marker is ovotransferrin or a functional fragment thereof.
  • the present invention provides the abovementioned methods for detecting intestinal barrier failure and for determining the extent thereof, respectively. This enables the farmer to make a qualified decision on whether or not measures for improving intestinal health are to be taken.
  • Measures against the development and/or against the progression of intestinal barrier failure involve feeding or administering health-promoting substances, such as zootechnical feed additives, or therapeutic agents.
  • health-promoting substances such as zootechnical feed additives, or therapeutic agents.
  • administered or related terms includes oral administration. Oral administration may be via drinking water, oral gavage, aerosol spray or animal feed.
  • zootechnical feed additive refers to any additive used to affect favorably the performance of animals in good health or used to affect favorably the environment. Examples for zootechnical feed additives are digestibility enhancers, i.e.
  • the health- promoting substances are selected from the group consisting of probiotic agents, praebiotic agents, botanicals, organic/fatty acids, zeolithes, bacteriophages and bacteriolytic enzymes or any combinations thereof.
  • testing procedures underlying the present invention may also be used for monitoring the intestinal health status in animals.
  • intestinal health status refers to status of the intestinal barrier.
  • the development or the progression of an intestinal barrier failure may be detected.
  • the effectiveness of measures taken against the development and/or against the progression of intestinal barrier failure may be controlled.
  • the present invention also pertains to an in vitro method for monitoring the status of the intestinal barrier in animals, the method comprising the following steps:
  • the at least one protein marker comprises or consists of ovotransferrin or a functional fragment thereof.
  • an increase in the amount of ovotransferrin over time indicates the development or progression of intestinal barrier failure.
  • a decrease in the amount of ovotransferrin over time indicates improvements in the intestinal health situation which may be caused by natural healing processes or by specific measures being taken against the development or progression of intestinal barrier failure.
  • an “increase” or a “decrease” in the amount of ovotransferrin typically refers to a statistically relevant amount.
  • the intestinal sample material is a pooled sample deriving from an avian flock and the at least one protein marker is ovotransferrin or a functional fragment thereof.
  • the amount of ovotransferrin may be monitored in test samples collected and analyzed in a weekly, daily our hourly manner.
  • excremental samples are collected and analyzed at consecutive days.
  • the excremental test samples may be taken and analyzed on a daily basis from birth to slaughter.
  • a first test sample is preferably taken and analyzed during the initial growth phase (starter phase, day 5 to day 10), a second test sample is taken and analyzed during the enhanced growth phase (day 11 to day 18) and, optionally, a third test sample is taken and analyzed on a later stage.
  • a first test sample is taken and analyzed in the initial growth phase and further test samples are taken and analyzed for example on a daily basis during the enhanced growth phase, optionally until slaughter.
  • a further aspect of the present invention is the use of ovotransferrin, or functional fragments thereof, as intestinal markers for detecting intestinal barrier failure in an animal subject or in an animal population.
  • a specific embodiment of the present invention is the use of ovotransferrin as a fecal marker for detecting intestinal barrier failure in an avian subject or in an avian population.
  • Applications of the methods according to the invention are for example (i) aiding in the diagnosis and/or prognosis of intestinal barrier failure caused by enteric diseases; (ii) monitoring the progress or reoccurrence of intestinal barrier failure or (iii) aiding in the evaluation of treatment efficacy for an animal population undergoing or contemplating treatment.
  • Applications of the invention in particular help to avoid loss in animal performance like weight gain and feed conversion.
  • predisposing factors consist of the administration of Gumboro vaccine to induce mild immunosuppression and a ten-fold dose of coccidiosis vaccine (either Paracox-8 or Hipracox, depending on the trial) to induce predisposing intestinal damage.
  • coccidiosis vaccine either Paracox-8 or Hipracox, depending on the trial
  • necrotic lesions animals were challenged with approximately 4.10 8 CFU of the netB-positive C. perfringens strain CP56 on three consecutive days, after which the animals were euthanized. At necropsy, lesion scoring in the small intestine (duodenum, jejunum and ileum) was performed as described by Keyburn et al.
  • Alpha-toxin of Clostridium perfringens is not an essential virulence factor in necrotic enteritis in chickens.
  • the samples were grouped according to the disease severity of the animal, leading to the following disease severity groups: birds that received all predisposing factors but were not challenged with C. perfringens : negative control; birds challenged with C. perfringens but no necrosis: score 0 or challenged with C. perfringens and various severity degrees: score 2 (mild), score 3-4 (moderate) or score 5-6 (severe).
  • Unprocessed cloacal material or homogenized litter material was thawed at room temperature.
  • the Spearman rank correlation was used to assess the relationship between the ovotransferrin concentration in the cloacal samples and either the necrotic enteritis lesion score or the coccidiosis score. Results were reported as means and standard error of the means (SEM).
  • fecal ovotransferrin levels were measured in birds with either experimental coccidiosis or necrotic enteritis, which both cause intestinal barrier failure, using different approaches.
  • ELISA analysis samples from different NE in vivo trials revealed that ovotransferrin was more abundant in samples from birds suffering from necrotic enteritis as compared to unchallenged birds.
  • elevated ovotransferrin concentrations were measured in samples from coccidiosis-positive birds as compared to their unchallenged controls. Fecal ovotransferrin levels were significantly correlated with the severity of intestinal barrier failure caused by either coccidiosis or necrotic enteritis.
  • the degree of gut barrier failure might be classified depending on the severity of the symptom on the affected sites (e.g. necrosis due to C. perfringens- induced necrotic enteritis), and the extent of the affected surface area.
  • the degree of gut barrier failure is more severe with NE as this is associated with necrosis, the extent (in terms of surface area) is higher with coccidiosis.
  • the measurement of an specific APP is a valuable tool to measure inflammation and concomitant intestinal barrier failure, as it can provide information on specific biological disease processes and is a useful tool to assess efficacy of molecules that reduce gastrointestinal disturbances.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un procédé in vitro pour détecter une défaillance de la barrière intestinale chez des animaux, le procédé comprenant les étapes suivantes : a) la collecte d'un matériau d'échantillon intestinal d'un animal individuel ou d'une population animale; et b) la détermination de la quantité d'au moins un marqueur protéique contenu dans ledit matériau d'échantillon; le ou les marqueurs protéiques comprenant ou étant constitués d'ovotransferrine ou d'un fragment fonctionnel de celle-ci, et une quantité accrue dudit au moins un marqueur protéique contenu dans ledit échantillon par rapport à un échantillon de référence indiquant une défaillance de la barrière intestinale.
EP19706290.4A 2018-03-02 2019-02-28 Procédé in vitro de détection d'une défaillance de la barrière intestinale chez des animaux par détermination de l'ovotransferrine Pending EP3759496A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18159632 2018-03-02
PCT/EP2019/054947 WO2019166534A1 (fr) 2018-03-02 2019-02-28 Procédé in vitro de détection d'une défaillance de la barrière intestinale chez des animaux par détermination de l'ovotransferrine

Publications (1)

Publication Number Publication Date
EP3759496A1 true EP3759496A1 (fr) 2021-01-06

Family

ID=61569071

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19706290.4A Pending EP3759496A1 (fr) 2018-03-02 2019-02-28 Procédé in vitro de détection d'une défaillance de la barrière intestinale chez des animaux par détermination de l'ovotransferrine
EP19706288.8A Pending EP3759495A1 (fr) 2018-03-02 2019-02-28 Procédé in vitro de détection d'une insuffisance de barrière intestinale chez des animaux

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19706288.8A Pending EP3759495A1 (fr) 2018-03-02 2019-02-28 Procédé in vitro de détection d'une insuffisance de barrière intestinale chez des animaux

Country Status (11)

Country Link
US (2) US20210011027A1 (fr)
EP (2) EP3759496A1 (fr)
KR (2) KR20200128413A (fr)
CN (2) CN111801579A (fr)
AR (1) AR114423A1 (fr)
BR (2) BR112020017971A2 (fr)
CA (2) CA3092472A1 (fr)
MX (2) MX2020009044A (fr)
RU (2) RU2020129391A (fr)
WO (2) WO2019166531A1 (fr)
ZA (2) ZA202005890B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3622082T3 (da) 2017-05-12 2023-06-12 Evonik Operations Gmbh Fremgangsmåde til påvisning af c. perfringens-inducerede sygdomme i en fugleflok
US20210011027A1 (en) * 2018-03-02 2021-01-14 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals by determining ovotransferrin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281251A3 (fr) * 1987-02-04 1988-09-28 International Immunoassay Laboratories, Inc. Procédé pour préparer une composition d'un échantillon fécal pour vérification par essai immunologique
UA78486C2 (uk) * 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
JP2004536136A (ja) * 2001-07-27 2004-12-02 エヌ・ヴイ・ヌートリシア 敗血症の防止及び／又は処置のための経腸組成物
WO2005001483A2 (fr) * 2003-06-27 2005-01-06 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Nouvelles methodes de diagnostic des troubles dementiels
US8252769B2 (en) * 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
ES2314694T3 (es) * 2004-07-28 2009-03-16 F. Hoffmann-La Roche Ag Factor 1 promotor de la insulina como elemento de referen-cia/marcador de la insuficiencia de celulas beta.
JP5038407B2 (ja) * 2006-06-14 2012-10-03 ジョンズ ホプキンズ ユニバーシティー 疾患のバイオマーカーとしてのアルブミン結合性タンパク質／ペプチド複合体
US20100267062A1 (en) * 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
EP3067694A1 (fr) * 2008-05-05 2016-09-14 Los Alamos National Security, LLC Préparation d'échantillons d'acide nucléique à base de flux latéral et régulation d'écoulement de fluide passif
CN102597258B (zh) * 2009-02-06 2016-02-17 阿斯图特医药公司 肾损伤和肾衰竭的诊断及预后
IT1406051B1 (it) * 2010-08-05 2014-02-06 D M G Italia S R L Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
RU2472162C1 (ru) * 2011-05-04 2013-01-10 Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко Россельхозакадемии Способ серологической диагностики вирусных желудочно-кишечных инфекций крупного рогатого скота методом иммуноферментного анализа
CN103732259A (zh) * 2011-06-24 2014-04-16 森彻斯有限公司 细胞外靶向药物缀合物
EP2626705A1 (fr) * 2012-02-13 2013-08-14 Institut d'Investigacions Biomédiques August Pi i Sunyer Utilisation de la forme soluble d'AXL pour le diagnostic et/ou le pronostic du syndrome d'insuffisance cardiaque
IN2014DN08537A (fr) * 2012-03-20 2015-05-15 Otago Innovation Ltd
JP2016530529A (ja) * 2013-09-05 2016-09-29 ユニヴァーシティ ヘルス ネットワーク 病気に対する重篤若しくは致命的な反応及び／又は治療反応の早期決定のためのバイオマーカー
RS64127B1 (sr) * 2014-08-06 2023-05-31 Envera Lic Llc Kompozicije bakterijskih spora za industrijske upotrebe
WO2016029051A1 (fr) * 2014-08-20 2016-02-25 Rhode Island Hospital Évaluation de l'insuffisance cardiaque et stratification du risque arythmique par mesure des protéines hu circulantes
EP3112474A1 (fr) * 2015-06-29 2017-01-04 Evonik Degussa GmbH Procédé de détection d'entérite nécrotique aviaire
CN105412319A (zh) * 2016-01-05 2016-03-23 邱钱勇 一种治疗慢性肾功能衰竭的中药制剂及其制备方法及应用
US20210011027A1 (en) * 2018-03-02 2021-01-14 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals by determining ovotransferrin

Also Published As

Publication number Publication date
US20210011027A1 (en) 2021-01-14
CN111801579A (zh) 2020-10-20
CA3092472A1 (fr) 2019-09-06
RU2020129428A3 (fr) 2022-03-09
EP3759495A1 (fr) 2021-01-06
BR112020017969A2 (pt) 2020-12-22
CA3092519A1 (fr) 2019-09-06
RU2020129428A (ru) 2022-03-09
KR20200128413A (ko) 2020-11-12
MX2020009045A (es) 2020-10-12
US20210003592A1 (en) 2021-01-07
RU2020129391A3 (fr) 2022-03-09
ZA202005890B (en) 2022-12-21
WO2019166534A1 (fr) 2019-09-06
BR112020017971A2 (pt) 2020-12-22
MX2020009044A (es) 2020-10-12
RU2020129391A (ru) 2022-03-09
RU2770104C2 (ru) 2022-04-14
WO2019166531A1 (fr) 2019-09-06
ZA202005887B (en) 2022-03-30
CN111819444A (zh) 2020-10-23
AR114423A1 (es) 2020-09-02
KR20200128412A (ko) 2020-11-12

Similar Documents

Publication Publication Date Title
McDevitt et al. Necrotic enteritis; a continuing challenge for the poultry industry
Thamsborg et al. Impact of Ascaris suum in livestock
Martínez-Pérez et al. Serological detection of Ascaris suum at fattening pig farms is linked with performance and management indices
Villanueva et al. Emerging infectious diseases in water buffalo: An economic and public health concern
Szyszka et al. Do the changes in the behaviours of cattle during parasitism with Ostertagia ostertagi have a potential diagnostic value?
Mphahlele et al. Anthelmintic resistance and prevalence of gastrointestinal nematodes infecting sheep in Limpopo Province, South Africa
RU2770104C2 (ru) Способ in vitro выявления недостаточности кишечного барьера у животных путем определения овотрансферрина
EP3622082B1 (fr) Procédé de détection de maladies induites par c. perfringens chez un troupeau de volailles
CA3122457A1 (fr) Methode in vitro de detection d'une dysbiose intestinale aviaire
WO2018206690A1 (fr) Procédé de détection de maladies induites par c. perfringens chez des animaux
Nielsen et al. Health Risks of Growing Horses Related to Exercise and Parasite Control
Kasab-Bachi Epidemiology of Clostridium perfringens and Clostridium difficile among Ontario broiler chicken flocks
Karadas et al. The effects of dietary phytase activity on the concentration of Coenzyme Q10 in the liver of young turkeys and broilers
Groves et al. Descriptive epidemiology of Spotty Liver Disease in Australian cage-free brown egg layer chicken flocks with a scratch area.
Hussein et al. Effect of amino acid supplementation to reduced crude protein diets on growth performance, organ weights and nutrient digestibility of broiler chickens exposed to sub-clinical enteric health challenges
Röhe Impact of dietary protein and fiber on the nutritional physiology of poultry
Dixon et al. PSI-30 Identifying key regulator genes associated with parasite resistance and their link with climate conditions in sheep.
Marchal et al. Feeding broilers total inorganic phosphorus free diets with phytase maintained normal performance as shown in 4 independent trials
Leishman Hypothalamic-Pituitary-Adrenal Axis Activity and Robustness: Working Towards Better Breeding of Canadian Turkeys
Seyoum et al. Research Article Morbidity Parameters Associated with Gastrointestinal Tract Nematodes in Sheep in Dabat District, Northwest Ethiopia
Pittman Effect of fenbendazole on shedding and embryonation of Ascaris suum eggs in naturally infected gestating sows
Hafez World’s Poultry Science Association Federation of European Branches
Thamsborg et al. Ascaris: The Neglected Parasite: Chapter 14. Impact of Ascaris suum in Livestock
Fthenakis Christos Brozos, DVM, PhDa, Vasia S. Mavrogianni, DVM, PhDb
Caballero et al. Mycotoxins in poultry–External signs can give a hint

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200828

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210629